AC Health, the healthcare arm of the Ayala Group, is targeting to become a $2-billion enterprise by 2035 as it marks its 10th anniversary and outlines a roadmap for nationwide expansion and deeper integration across its healthcare ecosystem.
“What we’re building is a healthcare group designed for the long haul,” said AC Health President and CEO Paolo Borromeo. “We are backed by an ecosystem that is rooted in our commitment to providing quality, accessible healthcare for every Filipino.”
Since its first investment in Generika Drugstore in 2015, AC Health has evolved into a fully integrated platform, now comprising 236 corporate and multispecialty clinics and six hospitals under the Healthway Medical Network.
The group also operates 880 pharmacies through Generika and St. Joseph Drug and holds 1,178 certificates of product registration via its pharmaceutical units I.E. Medica and MedEthix.
In 2024, the company posted a 10% revenue increase to PHP 9.4 billion. Its provider network under Healthway recorded a 22% rise in revenues, outpacing the hospital industry’s 8% growth.
Meanwhile, its pharma group, PETT, delivered positive results despite a 5% contraction in the broader pharmaceutical industry.
To achieve its 2035 goal, AC Health plans to expand both organically and through acquisitions, with a focus on key urban areas including Cebu.
Over the next three years, the company aims to grow its ecosystem to 1,150 retail pharmacies, 300 clinics, and 10 hospitals.
Borromeo emphasized that the group’s long-term strategy is not just about scale but about delivering meaningful impact across the patient journey.
Business News Asia